Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy

被引:31
|
作者
Diepeveen, SHA
Verhoeven, GHWE
van der Palen, J
Dikkeschei, BLD
van Tits, LJ
Kolsters, G
Offerman, JJG
Bilo, HJG
Stalenhoef, AFH
机构
[1] Univ Med Ctr Nijmegen, Dept Nephrol 545, NL-6500 HB Nijmegen, Netherlands
[2] Isala Clin, Dept Internal Med, Zwolle, Netherlands
[3] Isala Clin, Dept Clin Chem, Zwolle, Netherlands
[4] Med Spectrum Twente, Dept Epidemiol, Enschede, Netherlands
[5] Univ Med Ctr Nijmegen, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 98卷 / 01期
关键词
end-stage renal disease; lipid peroxides; lag time of in vitro LDL oxidation; oxidized LDL; oxidative stress;
D O I
10.1159/000079921
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: In patients with end-stage renal disease (ESRD), cardiovascular complications are the main cause of death. Increased oxidative stress is one of the risk factors for enhanced atherosclerosis in this population. Literature data vary partially dependent on differences in methodology. The present study compares three different methods: plasma lipid peroxides, the newly developed measurement of circulating oxidized LDL(Ox-LDL) particles and the frequently used copper-induced LDL oxidation lag time. Methods: We assessed plasma lipid peroxides, circulating Ox-LDL and in vitro copper-induced LDL oxidation lag time in 47 non-diabetic patients with ESRD, at the start of renal replacement therapy, and compared these with 41 age- and sex-matched controls. Results: In ESRD, total cholesterol (4.6 +/- 1.1 vs. 5.6 +/- 0.9 mmol/l; p < 0.001), LDL cholesterol (2.8 +/- 0.8 vs. 3.5 +/- 0.7 mmol/l; p < 0.001) and HDL cholesterol (1.0 +/- 0.3 vs. 1.4 +/- 0.4 mmol/l; p < 0.001) were lower compared to controls. Plasma lipid peroxides were higher (1.1 +/- 0.5 vs. 0.8 +/- 0.5 mu mol/l; p = 0.003) in ESRD. No differences were observed in plasma Ox-LDL (63.1 +/- 62.0 vs. 55.3 +/- 48.0 mg/l). However, due to the lower plasma LDL cholesterol in ESRD, LDL oxidation level was increased in ESRD (7.1 +/- 0.1 vs. 4.2 +/- 0.3%; p = 0.03). LDL lag time was slightly longer (89 +/- 11 vs. 84 +/- 11 min; p = 0.04) in ESRD. There were no significant differences regarding the amount and rate of dienes produced. Conclusions: Elevated levels of lipid peroxides and higher LDL oxidation levels support the theory that ESRD is associated with increased oxidative stress, which may explain the accelerated atherosclerosis. The measured amount of oxidative stress is not reflected by in vitro oxidizability of LDL. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C3 / C7
页数:5
相关论文
共 50 条
  • [31] Hormone replacement therapy in postmenopausal women with end-stage renal disease
    Andreoli, SP
    KIDNEY INTERNATIONAL, 2000, 57 (01) : 341 - 342
  • [32] Clinical features, therapy, and outcome of calciphylaxis in patients with end-stage renal disease on renal replacement therapy: Case series
    Lee, Kian-Guan
    Lim, Amy Ee-Lin
    Wong, Jiunn
    Choong, Lina Hui-Lin
    HEMODIALYSIS INTERNATIONAL, 2015, 19 (04) : 611 - 613
  • [33] RENAL REPLACEMENT THERAPY FOR END-STAGE RENAL DISEASE PATIENTS IN RUSSIAN FEDERATION, 1998-2011 (Report of the Russian Registry of Renal Replacement Therapy)
    Tomilina, N. A.
    Bikbov, B. T.
    VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2015, 17 (01): : 35 - 58
  • [34] Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease
    Mathur, S
    Devaraj, S
    Jialal, I
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (02): : 141 - 147
  • [35] Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease
    Raj, DSC
    Dominic, EA
    Pai, A
    Osman, F
    Morgan, M
    Pickett, G
    Shah, VO
    Ferrando, A
    Moseley, P
    KIDNEY INTERNATIONAL, 2005, 68 (05) : 2338 - 2344
  • [36] Oxidative Stress in End-Stage Renal Disease: Pathophysiology and Potential Interventions
    Roumeliotis, Stefanos
    Liakopoulos, Vassilios
    Dounousi, Evangelia
    Mark, Patrick B.
    Oxidative Medicine and Cellular Longevity, 2023, 2023
  • [37] Renal replacement in end-stage renal disease patients over 75 years old
    Létourneau, I
    Ouimet, D
    Dumont, M
    Pichette, V
    Leblanc, M
    AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (02) : 71 - 77
  • [38] The use of sugammadex in end-stage renal failure with renal replacement therapy
    Binhas, M.
    Bouyoucef, A.
    Paul, M.
    d'Honneur, G.
    Plaud, B.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2012, 31 (12): : 972 - 973
  • [39] Renal replacement therapy in end-stage renal disease patients with chronic liver disease and ascites: Role of peritoneal dialysis
    Chaudhary, Kunal
    Khanna, Ramesh
    PERITONEAL DIALYSIS INTERNATIONAL, 2008, 28 (02): : 113 - 117
  • [40] The depression status of patients with end-stage renal disease in different renal replacement therapies
    Lin, Yu-Hua
    Yang, Yu
    Chen, Shu-Ya
    Chang, Chia-Chu
    Chiu, Ping-Fang
    Huang, Chih-Ying
    INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2011, 5 (01) : 14 - 20